Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03532009 Not yet recruiting - Heart Failure Clinical Trials

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

PRIORITIZE HF
Start date: June 18, 2018
Phase: Phase 2
Study type: Interventional

This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor (RAASi) therapy in heart failure patients.

NCT ID: NCT03530423 Not yet recruiting - Heart Failure Clinical Trials

Sensing Ventricular Arrhythmias by His Bundle Leads

Start date: May 2018
Phase:
Study type: Observational

The purpose of this trial is to determine if implantable cardiac device leads implanted in the His bundle are capable of detecting ventricular arrhythmias.

NCT ID: NCT03521934 Not yet recruiting - Clinical trials for Heart Failure-Type 2 Diabetes Mellitus

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Start date: June 14, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: - To demonstrate that sotagliflozin reduces cardiovascular (CV) mortality and morbidity (composite of CV death or hospitalization for heart failure [HHF]) compared to placebo in hemodynamically stable patients with type 2 diabetes (T2D) and heart failure (HF) with left ventricular ejection fraction (LVEF) <50%, after admission for worsening heart failure (WHF). - To demonstrate that sotagliflozin reduces cardiovascular (CV) mortality and morbidity (composite of CV death or hospitalization for heart failure [HHF]) compared to placebo in hemodynamically stable patients with T2D and HF irrespective of LVEF after admission for WHF. Secondary Objectives: - To demonstrate that, when compared to placebo in the toal patient population, sotagliflozin reduces the total number (i.e., including recurrent events) of the following clinical events: - Cardiovascular death, HHF or urgent HF visit. - To demonstrate that, when compared to placebo, sotagliflozin reduces: - The composite of positively adjudicated sustained ≥50% decrease in eGFR, chronic dialysis, renal transplant or positively adjudicated sustained eGFR <15 mL/min/1.73 m2 in the total patient population. - Cardiovascular death in patients with LVEF < 50%. - Cardiovascular death in the total patient population. - All-cause mortality in patients with LVEF < 50%. - All cause mortality in the total patient population. - To demonstrate the safety and tolerability of sotagliflozin in the total population in this study.

NCT ID: NCT03519477 Not yet recruiting - Clinical trials for Heart Failure,Congestive

Comprehensive Medication Monitoring on Heart Failure Patient Outcomes

Start date: July 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to usual care in a hospital setting.

NCT ID: NCT03516994 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

EQUALACP
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community. The two approaches are a structured approach with an advance care planning conversation led by a trained person using Respecting Choices (First Steps) and a patient-driven approach which includes a Five Wishes advance care planning form written in plain language. The study will determine which approach is more effective at increasing advance care planning within each racial group and reducing differences between the two groups in advance care planning.

NCT ID: NCT03515980 Not yet recruiting - Clinical trials for Congestive Heart Failure

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Start date: May 25, 2018
Phase: Phase 1
Study type: Interventional

This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.

NCT ID: NCT03515655 Not yet recruiting - Heart Failure Clinical Trials

A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)

Start date: July 1, 2018
Phase:
Study type: Observational

A study of participants hospitalized with acute heart failure with reduced ejection fraction

NCT ID: NCT03512782 Not yet recruiting - Heart Failure Clinical Trials

EFFECTIVENESS OF THE MONITORING OF SIGNS AND SYMPTOMS AFTER DISCHARGE FROM HOSPITAL OF PATIENTS WITH HEART FAILURE

CARDIOENF
Start date: May 1, 2018
Phase: N/A
Study type: Interventional

What is proposed in this project is to develop and evaluate the effectiveness of an online remote monitoring system that is easily accessible to patients so that professionals with experience in monitoring patients with heart failure (HF) can monitor signs and symptoms of decompensation of the disease, as well as self-care actions. A randomized, blind trial for outcome evaluation was designed that will include patients hospitalized for acute HF at a referral institution in cardiology in southern Brazil. Patients in the intervention group will be followed up with a remote monitoring system, accessible by device (computer, tablet and cell phone) connected to the internet, by checking for signs, symptoms and self-care actions in three moments during 30 days after hospital discharge. Patients in the control group will follow up according to the routine of the hospital or physician assistant. The primary endpoint for assessing the efficacy of the system will be hospital readmission within 30 days (follow-up period). The information regarding the signs, symptoms and self-care of the patients will be monitored by the research team through an access schedule. The sample calculation points to the need to include a total of 142 patients (71 in each group). The data will be analyzed through descriptive and analytical statistics. It is hoped that the development of a remote monitoring system could be characterized as a strategy for the early detection of signs and symptoms of acute decompensation in HF patients, impacting on hospital readmission rates within 30 days after discharge. In addition, remote monitoring of signs and symptoms may promote improved adherence and self-care of patients. The scientific contribution will occur to the extent to which there is innovation in patient follow-up and feedback obtained from the patient's interaction with the system.

NCT ID: NCT03511248 Not yet recruiting - Heart Failure Clinical Trials

Effect of Dietary Nitrate Ingestion in Heart Failure

DiNOmo-HF
Start date: April 2018
Phase: Phase 2
Study type: Interventional

This study evaluates the addition of inorganic dietary nitrate to the optimal treatment of patients diagnosed with heart failure with reduced ejection fraction. Some vegetables contain large amounts of inorganic nitrate, and research suggests that this nitrate has beneficial effects on the heart and blood vessels. We have shown in lab experiments that nitrate has positive effects on the heart. We wish to test whether dietary nitrate might be useful in halting deterioration and/or improving heart function in patients with heart failure, with a specific focus on a marker of poor outcome in heart failure: high uric acid levels. Half of the patients will receive nitrate-rich beetroot juice, and the other half a nitrate-deplete placebo beetroot juice.

NCT ID: NCT03509506 Not yet recruiting - Heart Failure Clinical Trials

A Self-care Mobile Health App in Individuals With Heart Failure

Start date: May 2018
Phase: N/A
Study type: Interventional

This study was designed to determine the potential benefits that individuals with heart failure (HF) could experience from using a mobile application.